On April 23, 2024 Apmonia Therapeutics, a biopharmaceutical company developing innovative cancer therapies, reported that it has secured additional non-dilutive financing for a total of €2.7M (Press release, Apmonia Therapeutics, APR 23, 2024, View Source [SID1234642241]). This new financing is part of France 2030 investment plan. Apmonia Therapeutics is one of the winners of the 11th edition of the i-Nov Innovation Contest (operated by Bpifrance), and will receive the largest amount of funding (€2.2M) among the 42 prizewinners. Additional funding (€0.5M) will be
granted as part of the regionalized Plan d’Investissement d’Avenir (PIA4), co-financed by the Grand-Est Region and the French Ministry of the Economy, Finance and Sovereignty.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Including previous fundraisings and financing already obtained, a total of €11M has been leveraged for the development of Apmonia Therapeutics’ technological platform.
A first clinical trial in patients with solid tumors, and a pioneering position in a new therapeutic class in oncology
Awarded a prize in the i-Nov competition, Apmonia Therapeutics’ INOTAX project aims to bring new therapeutic solutions to the medical need for solid tumor cancers. The company has identified and developed the first-in-class drug candidate TAX2, a peptide that acts as a modulator of the tumor
microenvironment by targeting the TSP-1/CD47 interaction.
At the same time, Apmonia Therapeutics’ scientific teams are working to develop new peptide-based therapies targeting the tumor microenvironment. Using advanced in silico technologies, the company
aims to identify new therapeutic targets and optimize the design of antagonistic peptides. This new financing will enable Apmonia Therapeutics to industrialize its drug discovery capabilities to accelerate
the development of new drug candidates.
"We are delighted to have won the i-Nov innovation contest, which testifies to the strong potential of our technological platform and our original approach", says Dr. Albin Jeanne, President of Apmonia Therapeutics, adding "This funding is a new milestone and a strong signal as Apmonia Therapeutics prepares to start its first clinical trial. It will also enable us to strengthen the development of our product pipeline, with potential applications in various pathologies".
"Bpifrance is proud to once again support one of France’s DeepTech nuggets, which has already been recognized on numerous occasions. Apmonia Therapeutics has an original technology and a management team whose expertise is widely recognized, and the funding granted today under both
the i-Nov innovation competition and the 4th Plan d’Investissement d’Avenir aims to foster the emergence of Apmonia Therapeutics as a leading company in its field, by supporting two strategic axes: clinical development prior to industrial and commercial launch, and portfolio diversification", explains
Lucie Jolibois, in charge of innovation at Bpifrance’s Champagne-Ardenne Regional Office.